Wen L, Lee I, Chen G, Huang J K, Gong Y, Krishnamoorthi R
Department of Chemistry, Western Illinois University, Macomb 61455.
Biochem Biophys Res Commun. 1995 Feb 27;207(3):897-902. doi: 10.1006/bbrc.1995.1270.
Cucurbita maxima trypsin inhibitor-V (CMTI-V) is also a specific inhibitor of human blood coagulation factor beta-factor XIIa. A recombinant version of CMTI-V has allowed probing of roles of individual amino acid residues including the reactive site residue, lysine (P1), by site-directed mutagenesis. The K44R showed at least a 5-fold increase in inhibitory activity toward human beta-factor XIIa, while there was no change toward bovine trypsin. This result demonstrates that beta-factor-XIIa prefers an arginine residue over lysine residue, while trypsin is non-specific to lysine or arginine in its binding pocket. On the other hand, the specificity of CMTI-V could be changed from trypsin to chymotrypsin inhibition by mutation of the P1 residue to either leucine or methionine (K44L or K44M).
南瓜胰蛋白酶抑制剂-V(CMTI-V)也是人凝血因子β-因子XIIa的特异性抑制剂。CMTI-V的重组版本使得通过定点诱变探究包括反应位点残基赖氨酸(P1)在内的单个氨基酸残基的作用成为可能。K44R对人β-因子XIIa的抑制活性至少增加了5倍,而对牛胰蛋白酶的抑制活性没有变化。该结果表明,β-因子XIIa在其结合口袋中更喜欢精氨酸残基而非赖氨酸残基,而胰蛋白酶对其结合口袋中的赖氨酸或精氨酸不具有特异性。另一方面,通过将P1残基突变为亮氨酸或蛋氨酸(K44L或K44M),CMTI-V的特异性可以从抑制胰蛋白酶转变为抑制胰凝乳蛋白酶。